Model‐Based Meta‐Analysis of Overall Survival in Vulnerable Platinum‐Ineligible NSCLC Populations
Open Access
- 16 February 2026
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (2) , e70197
Abstract
IPSOS (NCT03191786) is a Phase III trial comparing atezolizumab (atezo) monotherapy to single‐agent chemotherapy (gemcitabine or vinorelbine) in patients with treatment‐naïve locally advanced or metastatic NSCLC unsuitable for platinum‐doublet chemotherapy. The study demonstrated significant overall survival (OS) improvement in the atezo arm compared to single‐agent chemotherapy, with a stratified hazard ratio (HR) of 0.78 (95% CI: 0.63–0.97; p = 0.028). Since the IPSOS control arm only allowed gemcitabine or vinorelbine, a model‐based meta‐analysis (MBMA) was conducted, extracting OS data from published literature in similar patients, adjusting for population differences across trials, to estimate the HR between IPSOS arms versus historical trials which utilized single‐agent chemotherapies. The aim was to demonstrate the non‐inferiority of the IPSOS control arm versus historical controls. The literature search included patients who were chemotherapy‐naïve, had advanced or metastatic NSCLC, were platinum‐ineligible, ≥ 70 years or had ECOG ≥ 2, and were treated with single‐agent paclitaxel, docetaxel, gemcitabine, pemetrexed, or vinorelbine. Summary‐level OS data were extracted by digitizing Kaplan‐Meier curves, resulting in a database of 26 trials with 41 arms and 3637 participants. A nonparametric approach modeling the conditional probability of OS data was implemented. After adjusting for ECOG PS (the only significant covariate), the model‐predicted HR for the IPSOS control arm relative to historical trials was 0.543 (95% CI: 0.435–0.677), and the HR for the IPSOS atezo monotherapy arm was 0.418 (95% CI: 0.335–0.522). Overall, the MBMA results support the benefit of atezo seen in the IPSOS trial.Keywords
This publication has 14 references indexed in Scilit:
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2018
- Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall SurvivalJNCI: Journal of the National Cancer Institute, 2017
- When less is better: the safety and efficacy of reduced intensity gemcitabine in a difficult patient population with advanced non-small-cell lung cancerMedical Oncology, 2013
- Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancerCancer, 2007
- Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6Journal of Thoracic Oncology, 2007
- A Randomized Phase II Trial of Two Schedules of Docetaxel in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung CancerJournal of Thoracic Oncology, 2007
- Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027).2006
- Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinomaCancer, 2003
- Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcomeBritish Journal of Cancer, 2000
- Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institutionEuropean Journal of Cancer, 1996